|Bid||36.84 x 900|
|Ask||36.95 x 2200|
|Day's Range||36.47 - 38.09|
|52 Week Range||27.65 - 133.82|
|Beta (5Y Monthly)||0.69|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2022 - Aug 08, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||123.00|
Subscribe to Yahoo Finance Plus to view Fair Value for GH
PALO ALTO, Calif., May 23, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago. Among the 19 abstracts are oral presentations highlighting the use of real-world data to identify resistance to early treatment in advanced breast cancer and the use of enhanced biomarker analysis to evaluate progression-free survival data in metastatic
PALO ALTO, Calif., May 21, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC). These data were presented during an oral presentation at Digestive Disease Week 2022.
The recent price decline of 49% in Guardant Health, Inc.'s ( NASDAQ:GH ) stock may have disappointed insiders who...